The initial phase of the collaboration will focus on clinical decision-making processes, such as dose selection, understanding mechanisms of action, distinguishing between patient responders and non-responders,

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said on Thursday.

As part of the collaboration, the drugmaker will use Immunai's AI model of the immune system and machine learning for clinical decision-making in drug discovery and development The post Israeli AI startup forges $18m partnership with AstraZeneca for cancer drug trials appeared first on The Times of Israel.